Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
27 juin 2024 08h18 HE
|
Medicenna Therapeutics Corp.
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and...
Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe
26 juin 2024 07h47 HE
|
Medicenna Therapeutics Corp.
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®, at...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
03 juin 2024 08h00 HE
|
Medicenna Therapeutics Corp.
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:...
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
31 mai 2024 09h29 HE
|
Medicenna Therapeutics Corp.
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping...
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
22 mai 2024 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
13 mai 2024 07h00 HE
|
Medicenna Therapeutics Corp.
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the...
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
30 avr. 2024 11h07 HE
|
Medicenna Therapeutics Corp.
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp....
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
26 avr. 2024 08h00 HE
|
Medicenna Therapeutics Corp.
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp....
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
24 avr. 2024 10h05 HE
|
Medicenna Therapeutics Corp.
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity...
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
10 avr. 2024 06h30 HE
|
Medicenna Therapeutics Corp.
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2...